Vir Biotechnology, Inc.

Vir Biotechnology, Inc. (VIR) priced its initial public offering on Oct 11, 2019 at $20.00 per share, raising $142.9M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $2.19B. Goldman Sachs was lead-left underwriter, joined by J.P. Morgan, TD Cowen and Barclays. Cooley advised the company and Latham & Watkins advised the underwriters.

Vir Biotechnology, Inc. is a clinical-stage immunology company developing treatments and preventives for serious infectious diseases. It has assembled four technology platforms focused on antibodies, T cells, innate immunity and small interfering RNA through internal development, collaborations and acquisitions.

Status

IPO

Ticker

VIR

Exchange

Nasdaq Global Select

Priced

Oct 11, 2019

IPO price

$20.00

Raised

$142.9M

Market cap at IPO price

$2.19B

First filed

Sep 3, 2019

Underwriters

Goldman Sachs, J.P. Morgan, TD Cowen and Barclays

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.